Adaptimmune

NASDAQ: ADAP
Develops engineered T-cell therapies (TCR T-cells) to treat solid tumor and hematological cancers.
Develops engineered T-cell therapies (TCR T-cells) to treat solid tumor and hematological cancers.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Oxford, UK

Initial Investment

2014
Adaptimmune

Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and hematological cancers.